Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer

European Journal of Cancer

Volumn 48, Issue 1, 2012, Pages 24-29

  Fedele, P ^a   Marino, A ^a   Orlando, L ^a   Schiavone, P ^a   Nacci, A ^a   Sponziello, F ^a   Rizzo, P ^a   Calvani, N ^a   Mazzoni, E ^a   Cinefra, M ^a   Cinieri, S ^a,b  

^a A Perrino Hospital   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Capecitabine; Clinical benefit rates; Efficacy; Metastatic breast cancer; Metronomic chemotherapy; Tolerability

Indexed keywords

CAPECITABINE; NAVELBINE; TRASTUZUMAB;

ADULT; AGED; ANOREXIA; ARTICLE; BLOOD TOXICITY; BREAST METASTASIS; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, METRONOMIC; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 83255191654     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.06.040     Document Type: Article

References (24)

1. G. Liu, E. Franssen, and M.I. Fitch Patient preference for oral versus intravenous palliative chemotherapy J Clin Oncol 15 1 1997 110 115
2. Smith I. Goals of treatment for patients with metastatic breast cancer. Semin Oncol 2006;33(1 Suppl. 2):S2-5.
3. J.R. Gralow Optimising the treatment of metastatic breast cancer Breast Cancer Res Treat 89 Suppl. 1 2005 S9 15
4. Van Cutsem E, Twelves C, Cassidy J, et al. Xeloda Colorectal Cancer Study Group. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19(21):4097-106.
5. P. Fumoleau, R. Largillier, and C. Clippe Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer Eur J Cancer 40 4 2004 536 542
6. J. Finek, L. Holubec, and T. Svoboda A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer Anticancer Res 29 2 2009 667 670
7. J.L. Blum, V. Dieras, and P.M. Lo Russo Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients Cancer 92 7 2001 1759 1768
8. P. Reichardt, G. Von Minckwitz, and P.C. Thuss-Patience Multicenter phase II study of oral capecitabine in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy Ann Oncol 14 8 2003 1227 1233
9. O'Shaughnessy J, Blum J. A retrospective evaluation of the impact of dose reduction in patients treated with Xeloda (capecitabine). Proc Am Soc Clin Oncol 2000;19 [abstr 400].
10. Y.S. Yap, A. Kendall, and G. Walsh Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer - how low can you go? Breast 16 4 2007 420 424
11. C. Sezgin, E. Kurt, and T. Evrensel Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome South Med J 100 1 2007 27 32
12. C. Andreetta, C. Puppin, and A. Minisini Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer Ann Oncol 20 2 2009 265 271
13. E. Munzone, A. Di Pietro, and A. Goldhirsch Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report Breast 19 1 2009 33 37
14. R.S. Mehta Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox J Clin Oncol 26 19 2008 3286 3288
15. M. Colleoni, L. Orlando, and G. Sanna Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects Ann Oncol 17 2 2006 232 238
16. U. Emmenegger, and R.S. Kerbel Five years of clinical experience with metronomic chemotherapy: achievements and perspectives Onkologie 30 12 2007 606 608
17. Zielinski C, Gralow J, Martin M. Optimizing the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed? Ann Oncol 2010; doi:10.1093/annonc/mdq069.
18. Stockler M, Sourjina T, Grimison P, et al. A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first line chemotherapy for advanced breast cancer. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):1031.
19. Martin M, Calvo L, Martinez N, et al. Randomized, phase II trial comparing continuous versus intermittent capecitabine monotherapy for metastatic breast cancer (MBC). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2009;27(15S):1086.
20. E.L. Mayer, and H.J. Burstein Chemotherapy for metastatic breast cancer Hematol Oncol Clin North Am 21 2 2007 257 272
21. N.S. Wong, R.A. Buckman, and M. Clemons Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response J Clin Oncol 28 5 2010 723 730
22. Burstein HJ, Spigel D, Kindsvogel K, et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. Breast Cancer Res Treat 2005;94(Suppl. 1):S6 [abstract 4].
23. S. Dellapasqua, F. Bertolini, and V. Bagnardi Metronomic cyclophosphamide and capecitabine with bevacizumab in advanced breast cancer J Clin Oncol 26 2008 4899 4905
24. Clinical trials.gov [Internet]. Efficacy of capecitabine metronomic chemotherapy to triple-negative breast cancer (SYSCBS-001). Available from: http://clinicaltrials.gov/ct2/show/NCT01112826.